Table 2.

Chemotherapy regimens used after progression following second-line chemotherapy

	Platinum combination therapy		Docetaxel monotherapy
	Third-line	≥Fourth-line	Third-line	≥Fourth-line
EGFR-TKI
Gefitinib	1	1	11	5
Erlotinib	2	0	5	7
Single agent
Docetaxel	0	1	-	1
Pemetrexed	2	0	2	3
Amrubicin	2	1	8	11
Gemcitabine	0	1	16	8
S1	0	0	5	12
Others	2	0	1	5
Platinum combination	3	0	0	5
Investigational agent	0	0	1	4

Abbreviations: EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor.